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De-novo malignancies after kidney transplantation represent one major cause for mortality
after transplantation. However, most of the studies are limited due to small sample size,
short follow-up or lack of information about cancer specific mortality.
Methods
This long-term retrospective analysis included all adult patients with complete follow-up that
underwent kidney transplantation between 1995 and 2016 at our centre. All patients with diagno-
sis of malignancy excluding non-melanoma skin cancer (NMSC) were identified and a matched
control group was assigned to the kidney transplant recipients with post-transplant malignancies.
Results
1417 patients matched the inclusion criteria. 179 malignancies posttransplant were diagnosed
in 154 patients (n = 21 with two, n = 2 patients with three different malignancies). Mean age at
cancer diagnosis was 60.3±13.3 years. Overall incidence of de-novo malignancies except
NMSC was 1% per year posttransplant. Renal cell carcinoma was the most common entity (n
= 49, incidence 4.20 per 1000 patient years; cancer specific mortality 12%), followed by cancer
of the gastro-intestinal tract (n = 30, 2.57; 50%), urinary system (n = 24, 2.06; 13%), respiratory
system (n = 18, 1.54; 89%), female reproductive system (n = 15, 1.29; 13%), posttransplant
lymphoproliferative disorders and haematological tumours (n = 14, 1.20; 21%), cancers of
unknown primary (n = 7, 0.60 100%) and others (n = 22, 1.89; 27%). Male sex, re-transplanta-
tion and time on dialysis were associated with de-novo malignancies after transplantation.
Conclusion
De-novo malignancies continue to be a serious problem after kidney transplantation. To
improve long-term outcome after Kidney transplantation, prevention and cancer screening
should be more tailored and intensified.
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Introduction
Transplantation is the best treatment for end-stage diseases of solid organs and provides
increased patient survival, and better quality of life [1]. Besides the undisputable advantages of
transplantation, an increased incidence of malignancies after solid-organ transplantation
(SOT) was shown [2–5]. The risk varies for all malignancies and is believed to be multifactorial
but possibly triggered by the chronic exposure to immunosuppressive agents [6–8]. With the
improving long-term outcome after transplantation, de-novo malignancies have become one
of the three major causes of death after transplantation while death from cardiovascular disease
and infections are decreasing in frequency [9, 10].
Almost 2/3 of the transplanted organs worldwide in 2016 were kidneys and the kidney has
been the most transplanted organ in Germany, too [11, 12]. With regard to this large number
of kidney transplantations (KT), knowledge of malignancies after KT is increasingly important
in all organ transplant programs. It was shown that de-novo malignancies after KT represent a
serious problem and incidence has raised [13]. However, mortality might not be increased due
to competing risk of death [14]. Calculating incidences and mortalities is difficult. Most of the
epidemiological studies on posttransplant malignancies are limited due to small sample size,
short follow-up intervals, lack of cancer specific mortality rates, or based on data from national
registers. National registers have big advantages and cover a lot of patients but reporting of
cancer to registries is often incomplete. As a consequence the true incidence and mortality
might be underestimated. The present study systematically reviewed the medical records of
the Universitätsmedizin Charité Berlin and data from the local cancer registry. It aims to
describe risk factors, distribution, incidence and mortality of malignancies after KT.
Materials and methods
All study procedures were approved by the institutional Ethics Committee (Ethikkommission
Charité Berlin, Ethikausschuss 1 am Campus Charité Mitte; Antragsnummer: EA1/048/14).
Inclusion criteria
The present study retrospectively investigated all adult patients (age at transplantation� 18
years) with a complete follow-up, who underwent the first KT between 01.01.1995 and
31.12.2016 at our centre (n = 1417). The cohort was assembled using the clinical hospital docu-
mentation system and the documentation system of the department of transplantation. All
patients were observed from the day of transplantation (the date of the first transplantation
was chosen for re-transplanted patients) until 31/07/2017, the last visit in the centre or date of
death, whichever occurred first. All participants signed a consent form and agreed to data
acquisition for research studies when listed for transplantation. None of the transplant donors
was from a vulnerable population and all donors or next of kin provided written informed
consent that was freely given according to national laws and regulations within Eurotrans-
plant. All medical costs, for organ donors and recipients were covered by the national health
insurance systems. Living related and unrelated organ donation was according to German
transplantation law. All living donors had undergone evaluation by an independent living
donor ethics committee. Deceased donors were allocated through Eurotransplant regular allo-
cation process.
Immunosuppression
Most patients initially received a standard immunosuppressive protocol including induction
therapy (anti-IL2-R antibody), calcineurin inhibitor, mycophenolate and steroids. ATG was
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rarely used in our cohort as initial immunosuppression [15]. Tapering of steroids was per-
formed with the intention of achieving a steroid-free regimen after the first year, if no rejection
episodes had occurred.
Patient groups and malignancies
All included patients were screened for malignant tumours according to the ICD-10 classifica-
tion. Non-melanoma skin cancer (NMSC; ICD-10 code: C44) was not assessed as malignancy
in this study. Malignant tumours were identified using the electronic patient records of the
outpatient clinic, the clinical information system and the database of the Charité Comprehen-
sive Cancer Center (CCCC). The CCCC is a local cancer registry that integrates all informa-
tion about tumour patients and also receives data from the residents´ local cancer registry (e.g.
date of death). Consequently, the data about patients after KT at our centre is very complete
and lacking hardly information. The time to the occurrence of the initial malignant cancer
after KT was obtained for all individuals. The reoccurrence of the same cancer entity was
counted as a single tumour event. For patients whose first malignancy appeared before the
date of transplantation the time to the first occurrence of any subsequent cancer posttransplant
was used in this analysis. If no malignant cancer posttransplant was diagnosed during the time
of observation, patients were added to the control group.
Each tumour patient was assigned to one patient of the tumour free control group, the
“matched control”. Consequently number of matched controls is identical to number of
patients with malignancy. The goal of this matching procedure was to reduce bias due to epi-
demiological differences between the tumour free control group and the patients with tumour.
Hence, the controls were matched in time of observation after KT (time under immunosup-
pression could not be shorter in matched controls), in patient´s age (age at transplantation ±4
years) and era of transplantation (year of transplantation ±4 years). If the malignancy was sex-
related (e.g. cancer of the prostate gland) the sex had to be identical. If there was more than
one possible match the same sex was preferred.
Statistics
SPSS (Version 24.0.0.0, IBM, Chicago, IL, USA) was used to calculate all results. Results are
displayed as average +/- standard deviation (SD) if skewness was between -1 and 1, otherwise
mean +/- SD or IQR are shown. Data were tested for significant differences on the level
p<0.05 either using the t-test (normally distributed data) or Man-Whitney-U-test (other
data). The cumulative risk of malignancy, the predicted incidence of cancer, the survival after
transplantation and the survival after the diagnosis of a malignancy were calculated by using
the Kaplan-Meier-Method.
Results
Epidemiological results after renal transplantation
1417 Patients (39% females) matched the inclusion criteria of whom 154 developed 179 malig-
nancies (23 patients had multiple malignancies) during the period of observation (11666
patient years). Previous analyses described time under immunosuppression (“time of observa-
tion”) and age at transplantation as two major predictors for de-novo malignancies after SOT
that bias comparisons on outcome [13, 16]. Also in the present cohort, tumour patients were
older and showed a longer follow-up compared to “all patients without malignancy” (Table 1).
Hence, a tailored control group (“matched controls”) was selected accordingly from all con-
trols. The matched controls showed consequently no statistically significant differences in “age
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at transplantation” and “time of observation” (Table 1). Nevertheless, some associated factors
for the appearance of de-novo malignancies were detected. Patients with malignancies under-
went more re-transplantations, received fewer kidneys from living donors, had a longer period
of dialysis before the transplantation and had more frequently the male sex. Statistically signifi-
cant differences in survival of the graft after transplantation as well as the number of mis-
matches between the groups were not detected (Table 1).
Characteristics and distribution of all malignancies
179 malignancies after transplantation were found in 154 patients (21 patients developed two dif-
ferent malignancies, in two patients three different malignancies were found). 16 of these malig-
nancies were diagnosed after the ending of immunosuppressive therapy following terminal graft
loss. In one of the 154 tumour patients cancer became clinically evident<4 weeks after KT and
was probably pre-existing, in another the cancer was transmitted via the allograft organ [17].
The most frequent malignancy screened posttransplant was renal cell carcinoma (RCC, Table 2).
It represented more than a fourth of all found malignancies with the highest incidence (Fig 1;
Table 2). Together with the cancer of the gastrointestinal tract (GIT, summarizing malignancies
of colon, pancreas, oesophagus and liver) and cancers of the urinary system (URO, summarizing
prostate gland, bladder, ureter and testicle), the three most frequent tumour entities represented
more than 50% of all malignancies (Fig 1; Table 2). Cancers of the lung and the bronchial tubes
(LUNG) had an incidence of 1.54 per 1000 patient years (Table 2) and represented 10% of all
diagnosed tumour entities (Fig 1). The malignancies of the female reproductive system charac-
terised by vagina, uterus, ovaries and breast, were summarized as GYN and represented 8.4% of
all tumours. Seven cancers of unknown primary (CUP, incidence 0.60, Table 2) were detected.
Posttransplant proliferative disorders (PTLD) (n = 3) were diagnosed according to the classifica-
tion of the World Health Organization (WHO) and summarized in HEMA, together with other
haematological tumours [18, 19]. The tumour entity “other” represents all other malignancies,
mainly cancer of the skin (malignant melanoma), Kaposi´s sarcoma and malignancies of head
and neck (larynx, tonsils, pharynx and thyroid gland) (Fig 1; Table 2).





p all patients without
malignancy
p
n = 154 n = 154 n = 1263
age at transplantation years (±SD) 54.5 (±13.9) 54.5 (±13.8) 0.996 49.3 (±14.8) <0.001
age at tumour diagnosis� years (±SD) 60.3 (±13.3) n/a n/a
donor age years (±SD) 53.4 (±15.5) 55.2 (±15.1) 0.314 52.7 (±14.7) 0.586
living donations n (%) 36 (23%) 45 (29%) 0.300 428 (34%) 0.008
time of observation after transplantation years
(±SD)
9.8 (±5.1) 10.8 (±4.7) 0.060 8.0 (±5.3) <0.001
female sex n (%) 46 (30%) 61 (40%). 0.094 507 (40%) 0.014
re-transplantation during follow-up n (%) 12 (8%) 4 (3%) 0.069 38 (3%) 0.008
dialysis before transplantation months (IQR) 49 (27–74) 32 (16–67) 0.011 43 (17–77) 0.212
mismatches n (±SD) 2.8 (±1.7) 2.9 (±1.7) 0.554 2.7 (±1.7) 0.658
follow-up after diagnosis of tumour† years (±SD) 4.0 (±3.8) 5.0 (±3.6) 0.013 n/a
transplant 5-year survival censored for death 88.7% 91.4% 0.448 87.6% 0.645
transplant 10- year survival censored for death 73.1% 78.5% 0.573 74.2% 0.708
� age at the first tumour diagnosis was chosen for the 23 patients with multiple malignancies.
† in matched controls: follow-up after corresponding moment in time after transplantation.
https://doi.org/10.1371/journal.pone.0242805.t001
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RCC mainly affected males and was characterised by the lowest mortality rate, likewise,
URO rarely affected females and showed low rates of cancer specific death (Table 2). Com-
pared to other tumours and specifically to RCC and GIT, URO appeared early after
Table 2. Characteristics at diagnosis of malignant tumours after kidney transplantation.
tumour entity n time of diagnosis after Tx years (±SD) age at diagnosis years (IQR) female sex n mortality due to tumour entity n (%) incidence †
RCC 49 6.7 (±4.9) 61 (48–69) 6 (12%) 6 (12%) 4.20
GIT 30 5.7 (±3.8) 69 (62–73) 7 (23%) 15 (50%) 2.57
URO 24 5.2 (±3.1) 66 (60–71) 2 (8%) 3 (13%) 2.06
LUNG 18 5.6 (4.6) 69 (64–75) 5 (28%) 16 (89%) 1.54
GYN 15 6.6 (±4.2) 44 (36–55) 14 (93%) 2 (13%) 1.29
HEMA 14 5.1 (±3.1) 57 (48–71) 6 (43%) 3 (21%) 1.20
CUP 7 9.5 (±4.9) 69 (63–74) 4 (57%) 7 (100%) 0.60
other 22 6.5 (±5.0) 64 (47–70) 8 (36%) 6 (27%) 1.89
all 179 6.2 (±4.3) 65 (52–71) 52 (29%) 58 (32%) 15.34
RCC–renal cell carcinoma, GIT–tumours of the gastrointestinal tract, URO–tumours of the urogenital tract, LUNG–tumours of the pulmonary tract, GYN–gynaecology
tumours, HEMA–PTLD and tumours of the blood cells, CUP–cancer of unknown primary, other–all other solid malignancies
† calculated per 1000 patient years.
https://doi.org/10.1371/journal.pone.0242805.t002
Fig 1. Percentage of the different tumour entities after kidney transplantation. RCC–renal cell carcinoma, GIT–
tumours of the gastrointestinal tract, URO–tumours of the urogenital tract, LUNG–tumours of the pulmonary tract,
GYN–gynaecology tumours, HEMA–PTLD and tumours of the blood cells, CUP–cancer of unknown primary, other–
all other solid malignancies.
https://doi.org/10.1371/journal.pone.0242805.g001
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transplantation (Table 2). A different outcome was seen after diagnosis of GIT. Both the per-
centage of affected woman and the mortality were elevated compared to RCC and URO
(Table 2). GYN developed in younger patients and also affected one man (Table 2) [17].
Tumour related mortality was particularly high in cases of lung cancer and CUP (Table 2).
Haematological malignancies as well as PTLD (summarized as HEMA) appeared comparable
early posttransplant and were similarly distributed between females and males (Table 2).
Incidence of the first malignancy
The incidence of the first malignancy (n = 154) after transplantation amounted to a total of
15.34 per 1000 patient years and is displayed for the first 10 years after KT in Fig 2. A predicted
tumour incidence for the first malignancy of 1.2% (CI 0.6–1.8%; males: 1.7%, CI 0.9–2.5%;
females: 0.6%, CI 0.0–1.2%) after one year was calculated, that increased to 6.2% (CI 4.8–7.5%;
males: 7.1%, CI 5.3–8.9%; females: 4.7%, CI 2.7–6.7%) after five and 14.0% (CI 11.6–16.6%;
males 15.8%, CI: 12.7–18.9%; females 11.1%, CI 7.6–14.6%) after ten years, respectively (Fig 2;
sex-specific data are shown in S1 Fig).
Fig 2. Incidence of the first malignancy after the first kidney transplantation. Incidence of the first malignant tumour for the
first ten years after kidney transplantation.
https://doi.org/10.1371/journal.pone.0242805.g002
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Survival after transplantation, after diagnosis of the first malignancy and
for specific tumour entities
The survival after KT was calculated for all included patients and is shown for patients with
malignancy (ntumour-group = 154) versus all patients without malignancies (nall-controls = 1263)
(Fig 3 –panel a) and matched controls (nmatch = 154) (Fig 3 –panel b). The calculated mortality
of the tumour-group after one year was 2.6% (CI 0.1–5.1%) compared to 3.0% (CI 2.1–4.0%,
all controls) and 0.0% (matched controls). The survival decreased over time to 83.6% (CI 77.8–
89.5%) after five and 62.0% (CI 53.7–70.2%) after ten years in the tumour-group. Controls
showed lower mortalities five (all controls: 10.6%, CI 8.8–12.5%; matched controls: 4.0%, CI:
0.9–7.2%) and ten years after KT (all controls: 24.8%, CI 21.8–27.8%; matched controls: 22.3%,
CI: 14.9–29.7%) to a statistically significant degree (Fig 3).
Besides the survival after KT, the survival of the tumour-group after diagnosis of the first
malignancy was calculated. The correspondent period after transplantation was followed for
each of the cancer-free matched controls. The analysis reveals a high mortality within the first
years after tumour diagnosis (mortality after one year 23.9%, CI: 17.1–30.7%) compared to
matched controls (4.1%, CI: 1.0–7.2%). The difference in survival is statistically highly signifi-
cant (p<0.001) and mortality remains elevated in the tumour-group after five (46.1%, CI:
37.4–54.8% versus 19.0%, CI 11.9–26.2%) and ten years (63.1%, CI: 52.8–73.4% versus 46.6%,
CI: 34.1–59.1%) (Fig 4).
Patients´ survival after diagnosis of a malignant cancer was also calculated for the different
tumour entities and is summarized in Table 3. The estimated 1-year survival after diagnosis of
RCC was high and remained high over time (Table 3) with only little differences in survival
compared to matched controls (Fig 5 –panel a). The estimated survival within the first years
Fig 3. Survival after transplantation. Panel A–Transplanted patients with malignancy versus all controls (all transplanted patients without malignancy). Panel B–
Transplanted patients with malignancy versus cancer free matched-controls.
https://doi.org/10.1371/journal.pone.0242805.g003
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Fig 4. Survival after diagnosis of a malignant tumour. Survival after diagnosis of a malignant tumour of the cancer free
matched controls was calculated accordingly to the period after transplantation of the assigned tumour patient.
https://doi.org/10.1371/journal.pone.0242805.g004
Table 3. Estimated survival after the diagnosis of the first malignancy.
tumour entity patients with first malignancy 1-year survival 3-year survival 5-year survival
RCC 38 95% 89% 80%
GIT 28 61% 35% 21%
URO 23 87% 72% 66%
LUNG 15 38% 15% 8%
GYN 12 100% 100% 80%
HEMA 13 92% 85% 75%
CUP 6 17% 0% 0%
other 19 71% 54% 54%
all 154 76% 63% 54%
matched controls 154 96% 88% 81%
RCC–renal cell carcinoma, GIT–tumours of the gastrointestinal tract, URO–tumours of the urogenital tract, LUNG–tumours of the pulmonary tract, GYN–gynaecology
tumours, HEMA–PTLD and tumours of the blood cells, CUP–cancer of unknown primary, other–all other solid malignancies.
https://doi.org/10.1371/journal.pone.0242805.t003
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after diagnosis of cancers of the female reproductive system was even higher and decreased
slightly after five years (Table 3). Also the estimated survival after diagnosis of cancers of the
urinary system was high and did not differ to a statistically significant degree from matched
controls (Table 3; Fig 5 –panel c). Life expectancy after diagnosis of a tumour of the respiratory
Fig 5. Survival after diagnosis of specific carcinomas. Panel A—Survival after diagnosis of renal cell carcinoma. Panel B—Survival after diagnosis of cancer of the
gastrointestinal tract. Panel C—Survival after diagnosis of cancer of the urinary system. Panel D—Survival after diagnosis of cancer of the respiratory system.
Survival after diagnosis of a malignant tumour of the cancer free matched controls was calculated accordingly to the period after transplantation of the assigned
tumour patient.
https://doi.org/10.1371/journal.pone.0242805.g005
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system was low and showed a statistically significant difference to matched controls, similar
results were seen for CUP and GIT (Table 3; Fig 5 –panels b and d; S1 Table).
Discussion
Risk factors for the development of cancer and survival after
transplantation
With the improved long-term outcomes after kidney transplantation, the incidence of de-
novo malignancies after transplantation has risen [13]. The present investigation systemati-
cally screened for tumours in all patients who underwent the first kidney transplantation
between 01.01.1995 and 31.12.2016 at our centre. Epidemiological data such as age at trans-
plantation, age at tumour diagnosis and cancer incidence is in line with data from Europe
(Table 1) [10, 20]. Compared to the general population transplanted people are young at diag-
nosis of cancer [13, 21–23]. The present investigation underpins this finding. The present
cohort was younger at tumour diagnosis (65 years [IQR 52–71], Table 2) compared to national
analysis of the German tumour population (mean age of 69–70 years) [24]. The younger age at
tumour diagnosis even persists after excluding RCC from the present analysis (mean age at
tumour diagnosis without RCC: 66.1±13.5 years) that is well known to be associated with
ESRD in younger transplant recipients. The mean age at first tumour diagnosis was even
much younger, both in all 154 transplanted patients with malignancy (60.3±13.3 years
[Table 1]) and in the 116 patients whose first tumour was not RCC (mean age at tumour diag-
nosis after excluding RCC as first tumour: 61.3±13.6 years). An earlier investigation found an
association between deceased kidney donation and recipients´ age at transplantation [25].
This was also seen in the present investigation. However, matched-controls received more
likely a living donation (29%) than patients with malignancy (23%). Although this difference
was not statistically significant it points towards a potential association between de-novo
malignancies and deceased donor transplantation. Also other earlier associations as male sex,
numbers of re-transplantations and time on dialysis before KT were seen in the present study
(Table 1) [10, 13, 16, 21, 23, 26, 27]. Nevertheless, it was hypothesized that time on dialysis
might trigger pre-existing cancers rather than de-novo malignancies [2]. The fact that the kid-
ney transplantation itself is a risk factor for malignancies is furthermore underpinned by the
moment of a tumour´s development: a steep increase of the incidence of the first malignancy
was seen within the first two years after transplantation (1.2% per year). Later incidence still
increases constantly but levels off over time (Fig 2). Yet, it remains elevated compared to the
general German population (0.35% in women, 0.43% in men, respectively; data from 2013)
[24]. The cancer incidence of the present investigation is in line with previous single-centre
studies as well as data from the Australia and New Zealand Dialysis and Transplant Registry
although higher compared to data from US registries [13, 28–30]. 44.6% malignancies were
found five, 81.0% malignancies ten years posttransplant, respectively. This is in line with ear-
lier investigations from Hungary (20% within the first year) and the greater Munich area (45%
five, 71% ten years after KT) [13, 16]. Earlier studies explained this phenomena with the theory
of dormant malignancies that are antedated and accelerated by the immunosuppression after
KT [13]. This theory consequently leads to a lower mean of age at diagnosis and helps to
explain the association between the time of observation and incidence of malignancies
(Table 1) [2, 13, 16, 20, 31]. Moreover, malignancies after transplantation seem to correlate
with a higher mortality, an excess risk of cancer-related death of over 2.5 times was shown
after KT [2]. The present data also showed significantly worse survival in the tumour-group,
both after KT (Fig 3) and after tumour diagnosis (Fig 4). Similar to earlier investigations, mor-
tality after tumour diagnosis was elevated [20, 32]. However, the differences to matched
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controls were mainly seen within the first years after diagnosis and mortality rates became sim-
ilar later (Table 3; Fig 4). Moreover, after a survival of around four years with malignancy the
further expectancy of life was hardly altered compared to kidney-transplanted patients without
tumour. Cancer specific mortality varied by age, sex, year of transplantation and type of can-
cer. Most of the patients with cancer specific cause of death died within these first four years
after diagnosis [2]. Interestingly, the 5- and 10-year survival of the transplant did not differ sig-
nificantly between the groups (Table 1).
Specific cancers and their epidemiological analyses
The distribution and frequency of cancer types varies by the transplanted organ and differs to
the general population [2, 16]. The high prevalence of renal cell carcinoma (RCC), malignan-
cies of the gastro-intestinal tract (GIT) and malignancies of the urinary system (URO) (Fig 1;
Table 2) were also seen in earlier investigations, both in single-centre observations and
national registries [20, 33, 34]. In Germany in 2014 RCC represented with 2.4% of all new can-
cers in females (3.8% in males) the 11th most common tumour entity (6th most common entity
in males, respectively); incidence was specified with 13.3 in females (23.9 in males, respec-
tively) per 100´000 patient years [24]. It was already shown that RCC is specifically increased
after KT and even approximately 4,9–15 fold more common compared to the general popula-
tion and other organ recipients [16, 29, 31, 34–36]. The malignant transformation of kidney
cysts was assumed as one possible explanation [20, 37].
According to the literature mortality of RCC was low in the present investigation, even the
lowest among all investigated malignancies (Table 2) [2, 38]. Interestingly, the survival after
diagnosis of RCC seems to be similar after KT (80% after five years; Table 3) compared to the
data of the national registry (77%) [24]. This is in line with data after KT from the Frankfurt
Transplant Center (83.5%) and Portugal (91.3%) [29, 38]. The good outcome of RCC after KT
might be caused by early detection of smaller cancer sizes, asymptomatic malignancies, low-
stage and low-grade tumours due to the intensive monitoring of patients with end stage renal
diseases posttransplant [20, 23].
Cancers of the gastro-intestinal tract are common after SOT and in the general population
[16, 24, 36, 39]. In Germany, almost every 8th cancer affects the colon. Colorectal cancer is even
the second most frequent tumour entity in women (third in men) with a proportion of 26% of
all carcinomas (33% in man, respectively). The incidence for Germany was calculated with 67.6
per 100´000 patient years for women (83.4 for man) [24]. Rocha et al. counted colorectal cancer
even as the most frequent non-cutaneous tumour after KT, in contrast to a Swiss investigation
that did not find a statistically significant increase [20, 39]. Also in the present investigation can-
cers of the bowel (mainly colorectal cancer) represented a big proportion of the GIT category
(17/30; S1 Table). Cancers of pancreas, oesophagus and liver (that were summarized as GIT in
the present investigation) are common entities, too [24]. Age at and time of diagnosis of GIT
after KT are in line with earlier publications [40]. Survival after colorectal cancer depends signif-
icantly on the stage of disease but is generally poor after SOT and worse compared to the gen-
eral population [5, 40–42]. This fact is underlined by the present investigation. Mortality is
elevated to matched controls (Tables 2 and 3, Fig 5 - panel B). The 5-year survival of 21% in the
GIT category is compared to the general German population rather on the level of pancreas car-
cinoma (8–9%) than colon carcinoma (51–52%) [24]. The poor outcome of the GIT category is
not a consequence of over-representation of tumours known to be associated with worse prog-
nosis. Mortality is high for all cancers, except stomach in this heterogeneous group (S1 Table).
Malignancies of the urinary system are increased after KT, but the increase of tumours of
the prostate gland (PC; n = 15) was less pronounced in the present investigation as described
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earlier [20, 29, 33, 38]. Two cancers of the bladder (ICD-10: C67; n = 6) were seen in females
while all other malignancies of the urinary system were seen in man (Table 2). However, the
true incidence of PC is difficult to calculate because the number depends on whether system-
atic screening (e.g. PSA, digital rectal examination) was performed or not. Independent of the
incidence, PC related death is rare [32, 38]. No one died as a direct consequence of PC in the
present investigation and survival was similar to matched controls (Fig 5 - panel c). Neverthe-
less, the estimated 5-year survival rate after tumour diagnosis was reduced (66%, Table 3) com-
pared to data of the general German population (76%), while incidence was elevated (2.05
[Table 2] versus 1.52 per 1´000 patient-years). Also the age at diagnosis is less in the present
cohort (66 years [IQR 60–71], Table 2) compared to national data (71–72 years) [24]. As PC
mainly affects older men, these patients probably died from competing risks after KT com-
pared to non-transplanted patients. Moreover, among urological tumours in patients after KT,
a higher rate of bladder cancers have been described earlier also for Germany [29]. Cancer of
the bladder is decreasing in frequency in the German population but remains a cancer of male
patients (about 75%) [24].
Tumours of the lungs and bronchial tubes are frequent malignancies after SOT, especially
in lung recipients but also after KT [5, 13, 20, 30, 37]. Moreover, it is common in the general
population and the second (males, 13,9%) and third (females, 8,5%) most common malig-
nancy in Germany [13, 24]. Even if the proportion seems to be similar in the German popula-
tion and in the present investigation, the incidence is not. The present investigation is in line
with international data after KT and elevated compared to data of the German tumour registry
(46.6 [females] and 89.5 [males] per 100´000 patient-years [24, 37]. The survival after this diag-
nosis is poor, both after KT (Table 3; Fig 5 - panel d) and in the general population (5 year: 15–
20%) [20, 24, 32]. Tobacco is the main risk factor, also after KT. Earlier investigations found
an increased risk for lung cancer after KT, especially in females, that was not seen in the pres-
ent study (Table 2) [10].
Cancers of the female reproductive system are sex-specific and mainly represented breast
cancers (Table 2). In the present investigation one male received breast cancer via the allograft
organ [17]. This is fortunately a very rare case [9]. With regard to German data (age at diagno-
sis of breast cancer: 64 years), the present cohort was younger at tumour diagnosis (44 year
[IQR 36–55], Table 2) and might not be included in the national mammography screening
program (50–69 years). Interestingly, the 5-year survival after tumour diagnosis is comparable
between the present cohort and German data (79–88%). [24].
Non-Hodgkin Lymphomas, as B-cell Lymphoma and PTLD, are common tumours after
SOT [30, 37]. The incidence of PTLD varies between the authors and countries and correlates
with a comparable high mortality similar to the present data (Table 2) [30, 43, 44].
Strengths of the present investigation are the complete and long follow-up after KT in one
single centre with the entire medical history of every kidney-transplanted patient including
data of the local cancer registry. As a consequence one limitation is the reduced number of
patients. Another limitation is the data on immunosuppression. Switching immunosuppres-
sant doses and drugs is nowadays a common practice, which makes the precise description of
immunosuppressive load rather complex [45]. Even if the exact IS regime of each patient
could not be considered, this potential confounder was reduced by the matching procedure,
which accounted for time under immunosuppression, era of transplantation as well as patient
´s age and sex. Non-melanoma skin cancer (ICD-10: C44), a frequent cancer after SOT, was
not integrated in the present investigation as the dermatological follow-up is performed in
external departments and reliable complete data was not available [26, 36, 46].
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Conclusion
Incidence and mortality are increased and antedated under immunosuppression but the dura-
tion of dialysis seems to be associated with cancer, too [13, 47–49]. Although we cannot tell
how many cancers were recognised by cancer screening, early (and asymptomatic) detection
of malignancies might help to optimize long-term results after transplantation. Therefore, the
present investigation not only reinforces earlier postulations to perform national screening
programs more rigorously in kidney transplant recipients. With regard to present results, pre-
vious calls for a more tailored cancer screening after KT are strengthened [40, 50]. This can
include low dose CT scans of the chest in case of previous lung diseases or present or history of
smoking as well as more frequent colonoscopies and occult blood tests in renal transplant
recipients [51–54]. Our centre performs annual abdominal ultrasounds including the native
kidneys in order to detect RCCs at early stages. As kidney transplant recipients are younger at
tumour diagnosis, the expansion of national screening programs (e.g. mammography, colo-
noscopy, low dose chest CT) for this population should be discussed and investigated [54].
However, frequent co-morbidities are competing risks, which might reduce the benefit of stan-
dardized national cancer screening programs [9]. Consequently, further research is needed to
develop rationally tailored tumour screening programs for renal allograft recipients.
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Investigation: Felix A. Fröhlich, Fabian Halleck, Lukas Lehner, Eva V. Schrezenmeier, Marcel
Naik, Dmytro Khadzhynov, Oliver Staeck.
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